[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592823":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":32,"responsibleParty":62,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"No History of AD",null,"Healthy controls",{"label":13,"type":10,"description":14,"interventionNames":10},"Mild AD","Eczema Area Severity Index (EASI): scores \\\u003C7 will be considered mild AD",{"label":16,"type":10,"description":17,"interventionNames":10},"Severe AD","Eczema Area Severity Index (EASI): scores \\>21 will be considered severe",[19],{"name":20,"affiliation":5,"role":21},"Katrina Abuabara, M.D.","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Jie Zhu, MD","CONTACT","415-502-0433","Jie.Zhu2@ucsf.edu",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":31},"Katrina Abuabara, MD","415-514-9769","katrina.abuabara@ucsf.edu",[33,54],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"San Francisco VA Medical Center","RECRUITING","San Francisco","California","94115","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-122.41942,37.77493,{"lat":45,"lon":44},[48,52],{"name":49,"role":25,"phone":50,"phoneExt":10,"email":51},"Frank Asare-Bediako, BS","520-304-8529","frank.asarebediako@ucsf.edu",{"name":53,"role":21,"phone":10,"phoneExt":10,"email":10},"Theodora Mauro, MD",{"facility":55,"status":35,"city":36,"state":37,"zip":56,"country":39,"countryCode":40,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"UCSF Mt Zion Campus","94511",{"type":42,"coordinates":58},[44,45],{"lat":45,"lon":44},[61],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[65],{"name":66,"class":67},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH","100592823","sodium-in-the-skin-and-atopic-dermatitis-100592823",false,"NCT06998446","Sodium in the Skin and Atopic Dermatitis","SIS-AD","Inclusion Criteria:\n\n* Ages 50 years and above\n* Willing to undergo non-contrast MRI (e.g., no contraindications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips or pregnancy).\n\nExclusion Criteria:\n\n* History of autoimmune disease.\n* Cardiac events in the last six months.\n* Impaired function of the liver or kidneys (glomerular filtration rate \\\u003C60ml\u002Fmin).\n* Current use of medications that influence sodium excretion (e.g. thiazide diuretics, SGLT2 inhibitors and spironolactone), and\u002For chemotherapy or antibiotic treatment.\n* Currently receiving phototherapy or taking systemic medications for atopic dermatitis including cyclosporine, methotrexate, or other broad immunosuppressive medications.\n\n(Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the criteria for severe disease.)",true,"ALL","50 Years",{"count":79,"type":80},90,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above.\n\nThe study is designed to test whether diet and skin barrier function are associated with skin sodium concentration and whether skin sodium concentration is linked to atopic dermatitis and immune profiles over time.\n\nParticipants will be asked to complete questionnaires, provide bio samples, and undergo non-contrast sodium MRI at 2-3 time points over 3-24 months.",[84,85],"Eczema","Atopic Dermatitis",[87,88],"Sodium","Salt","2026-07-13",{"date":91,"type":92},"2026-07-14","ACTUAL",{"date":94,"type":92},"2025-05-12",{"date":96,"type":80},"2028-08-30",{"name":5,"class":6},2]